Content about cancer treatment

August 19, 2013

DrFuhrman.com informed the National Advertising Division that the company has discontinued certain advertising claims — including “anti-cancer” and cancer treatment claims — made for the company’s Immunotect dietary supplement.

NEW YORK — DrFuhrman.com on Monday informed the National Advertising Division that the company has discontinued certain advertising claims — including “anti-cancer” and cancer treatment claims — made for the company’s Immunotect dietary supplement.

The claims at issue were challenged by the Council for Responsible Nutrition.

NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.

July 31, 2013

The Natural Dentist, a line of therapeutic oral care products, and Dr. Susan Calderbank, a leading dentist in oral health for patients undergoing chemotherapy and head and neck radiation, announced a partnership to raise awareness about the oral complications of cancer treatments in a joint effort to help patients manage these often debilitating side effects.

MADISON, N.J. — The Natural Dentist, a line of therapeutic oral care products, and Dr. Susan Calderbank, a leading dentist in oral health for patients undergoing chemotherapy and head and neck radiation, today announced a partnership to raise awareness about the oral complications of cancer treatments in a joint effort to help patients manage these often debilitating side effects.

July 22, 2013

An announcement Monday by generic drug maker Sandoz gives a glimpse of what could happen in the United States when biosimilars start to become available.

HOLZKIRCHEN, Germany — An announcement Monday by generic drug maker Sandoz gives a glimpse of what could happen in the United States when biosimilars start to become available.

June 10, 2013

Drug maker Amag Pharmaceuticals has licensed the U.S. commercial rights to a treatment for a common side effect of cancer treatments from another company, Amag said Monday.

LEXINGTON, Mass. — Drug maker Amag Pharmaceuticals has licensed the U.S. commercial rights to a treatment for a common side effect of cancer treatments from another company, Amag said Monday.

Amag said it licensed the rights for MuGard, used to treat oral mucositis, a condition that affects about 400,000 cancer patients each year. The drug is an oral mucoadhesive that works by creating a gel coating over the oral mucosa to shield the membranes of the mouth and tongue.

April 2, 2013

The Natural Dentist has launched “Rinse for Relief,” an online resource for proper oral care aimed at cancer patients suffering from mouth sores and other oral ailments, the fourth most common side effect of chemotherapy treatments.

MADISON, N.J. — The Natural Dentist has launched “Rinse for Relief,” an online resource for proper oral care aimed at cancer patients suffering from mouth sores and other oral ailments, the fourth most common side effect of chemotherapy treatments. The initiative included the unveiling of RinseForRelief.com and a giveaway of one free sample of Healthy Gums Mouth Rinse, an all-natural product that works as an effective daily cleanser and helps prevent and reduce gum bleeding and inflammation.

February 8, 2013

Biotech drug maker Amgen plans to launch six biosimilar drugs starting in 2017, according to published reports.

NEW YORK — Biotech drug maker Amgen plans to launch six biosimilar drugs starting in 2017, according to published reports.

December 11, 2012

Aetna and Cardinal Health Specialty Solutions on Tuesday announced an evidence-based program designed to improve cancer care in Michigan.

HARTFORD, Conn. — Aetna and Cardinal Health Specialty Solutions on Tuesday announced an evidence-based program designed to improve cancer care in Michigan. This pathways initiative identifies clinical practices that improve cancer treatment and make it more affordable.

September 6, 2012

Walgreens will offer products and other resources for women who have fertility complications due to cancer treatment, under a partnership with Ferring Pharmaceuticals announced Thursday.

PARSIPPANY, N.J. — Walgreens will offer products and other resources for women who have fertility complications due to cancer treatment, under a partnership with Ferring Pharmaceuticals announced Thursday.

June 29, 2012

The Food and Drug Administration has granted priority review for an investigational cancer treatment created by Bayer and Onyx Pharmaceuticals.

WAYNE, N.J., and SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has granted priority review for an investigational cancer treatment created by Bayer and Onyx Pharmaceuticals.

The companies said Bayer's new drug application for oral multikinase inhibitor regorafenib initially was filed in April for the treatment of patients with metastatic colorectal cancer, whose disease has progressed after approved standard therapies. The FDA grants priority review to medicines that provide a treatment where little or no adequate therapy exists.

January 3, 2012

The Food and Drug Administration's Oncologic Drugs Advisory Committee will review a resubmitted new drug application for a cancer treatment made by Cell Therapeutics.

SEATTLE — The Food and Drug Administration's Oncologic Drugs Advisory Committee will review a resubmitted new drug application for a cancer treatment made by Cell Therapeutics.

The company said that the panel will review the NDA for pixantrone, which is designed to treat relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed two or more lines of prior therapy.

November 10, 2011

The Food and Drug Administration has accepted a new drug application for a skin cancer treatment developed by Roche.

BASEL, Switzerland — The Food and Drug Administration has accepted a new drug application for a skin cancer treatment developed by Roche.

Roche said that the FDA accepted its NDA for vismodegib, designed to treat advanced basal cell carcinoma in adults for whom surgery is considered inappropriate. The application was granted priorit review status and has a confirmed action date of March 8, 2012.

October 20, 2011

Look Good…Feel Better, a global program dedicated to boosting cancer patients’ self-esteem and confidence through lessons on appearance-related side effects of cancer treatment, has announced the details of 12 new partnership programs being launched to support Look Good...Feel Better during October’s Breast Cancer Awareness Month.

WASHINGTON — Look Good…Feel Better, a global program dedicated to boosting cancer patients’ self-esteem and confidence through lessons on appearance-related side effects of cancer treatment, has announced the details of 12 new partnership programs being launched to support Look Good...Feel Better during October’s Breast Cancer Awareness Month.

October 11, 2011

Colomer USA’s ethnic hair care brand Creme of Nature has partnered with Look Good…Feel Better to educate people on the services available for women who are battling cancer and want to enhance their appearance.

JACKSONVILLE, Fla. — Colomer USA’s ethnic hair care brand Creme of Nature has partnered with Look Good…Feel Better to educate people on the services available for women who are battling cancer and want to enhance their appearance.

Throughout October and November, Look Good…Feel Better leaflets can be found inside Creme of Nature product packaging to help spread the word about the organization and the support it provides for women who are undergoing cancer treatment.

August 2, 2011

The Food and Drug Administration has granted orphan drug designation to a chemotherapy drug made by Merrimack Pharmaceuticals for pancreatic cancer, the drug maker said Monday.

CAMBRIDGE, Mass. — The Food and Drug Administration has granted orphan drug designation to a chemotherapy drug made by Merrimack Pharmaceuticals for pancreatic cancer, the drug maker said Monday.

Merrimack announced that it received the designation for MM-398, described as a novel, stable, nanotherapeutic encapsulation of the chemotherapy drug irinotecan.

July 12, 2011

The Food and Drug Administration has granted orphan drug designation to a cancer treatment in mid-stage development made by German drug maker 4SC, the company said Tuesday.

PLANEGG-MARTINSRIED, Germany — The Food and Drug Administration has granted orphan drug designation to a cancer treatment in mid-stage development made by German drug maker 4SC, the company said Tuesday.

4SC announced that it received the designation for resminostat, currently in phase-2 clinical trials as a treatment for hepatocellular cancer, or HCC. The FDA grants orphan drug designation to drugs for diseases that affect fewer than 200,000 people in the United States.

July 11, 2011

Generic drug maker Amneal has launched three new liquid drugs, the company said Monday.

BRIDGEWATER, N.J. — Generic drug maker Amneal has launched three new liquid drugs, the company said Monday.

March 24, 2011

Bristol-Myers Squibb said its late-stage clinical trial for a cancer treatment, which currently is under review by the Food and Drug Administration, achieved its primary endpoint.

PRINCETON, N.J. — Bristol-Myers Squibb said its late-stage clinical trial for a cancer treatment, which currently is under review by the Food and Drug Administration, achieved its primary endpoint.

The company said its phase-3 trial for investigational compound ipilimumab, designed for previously untreated patients that were diagnosed with metastatic melanoma, improved overall survival. The study compared the combination of ipilimumab 10 mg/kg and chemotherapy (dacarbazine) with chemotherapy alone.

March 10, 2011

Hospira has received approval from the Food and Drug Administration for a generic cancer treatment.

LAKE FOREST, Ill. — Hospira has received approval from the Food and Drug Administration for a generic cancer treatment.

Hospira will offer 20-mg, 80-mg and 160-mg vials of docetaxel at a 10-mg/mL concentration. Docetaxel is a generic version of Sanofi-Aventis's Taxotere.

Hospira already markets docetaxel in Europe and Australia, the drug maker noted.

November 18, 2010

Pfizer got promising results from a late-stage clinical trial of a cancer treatment, the drug...

NEW YORK — Pfizer got promising results from a late-stage clinical trial of a cancer treatment, the drug maker said Friday.

 

Pfizer announced results of the phase-3 “AXIS 1032” trial of the kidney cancer drug axitinib, saying that it “significantly” extended the lives of patients with advanced renal cell carcinoma compared with Nexavar (sorafenib), made by Bayer HealthCare and Onyx Pharmaceuticals.

 

 

October 31, 2010

In a big boost to its growing specialty pharmacy operation, drug-distribution and health services giant...